TABLE 1.
Study population
| Characteristic | HLA-B*57+ subjects | HLA-B*57− subjects | P value |
|---|---|---|---|
| No. of subjects | 49 | 52 | |
| Gender (% men) | 52 | 37 | 0.16 |
| Age (yr) | 47 (42–51) | 46 (40–51) | 0.54 |
| Time since diagnosis (yr) | 13 (10–17) | 11 (7–14) | 0.02 |
| CD4/μl | 649 (465–951) | 752 (567–914) | 0.23 |
| % CD4 | 36 (28–47) | 37 (32–43) | 0.78 |
| CD8/μl | 677 (495–1,012) | 740 (586–918) | 0.54 |
| % CD8 | 37 (29–42) | 37 (33–44) | 0.58 |
| CD4/CD8 | 1.0 (0.7–1.4) | 1.0 (0.8–1.3) | 0.83 |
| Plasma RNA (copies/ml) | 12 (2–67) | 20 (4–62) | 0.52 |
| % elite controllersa | 40 | 24 | 0.13 |
| Amt of cellular HIV DNA (copies/106 PBMC) | 11 (10–27) | 20 (10–46) | 0.03 |
| % with <10 copies/106 PBMC of cellular HIV DNA | 43 | 30 | 0.20 |
a
Elite controllers have always had a viral load of <50 copies/ml at clinical follow-up since HIV diagnosis.